 Connection
Steven Bair to Lymphoma, B-Cell
This is a "connection" page, showing publications Steven Bair has written about Lymphoma, B-Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.104 |
|
|
|
-
Bair SM, Pinto N, Roth A, Verneris M, Haverkos B, Nicklawsky A, Ohm A, Jordan K, Murphy LA, Marians R, Mallo R, Orentas R, Adams C, Kamdar M, Fry T. Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2026 Oct; 32(10):1268.e1-1268.e12.
Score: 0.843
-
Bock AM, Feng L, Chauhan A, Falchi L, Merryman R, Godbole S, Thiruvengadam SK, Jallouk AP, Major A, D'Angelo C, Ayers A, Baron K, Farahat OM, Shouse G, Danilov A, Bair S, Lunning M, Bhaskar S, Herrera AF, Sawalha Y, Flowers CR, Crombie JL, Salles G, Epperla N, Ahmed S. Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab. Blood Adv. 2026 08 25; 10(16):5496-5504.
Score: 0.214
-
Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, Kamdar M. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):778-782.
Score: 0.046
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|